Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipratropium/Levosalbutamol FDC in stable COPD
NCT05890638Phase 3Recruiting
- Sponsor
- Neutec Group
- Start
- Aug 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ipratropium bromide, levalbuterol in chronic obstructive pulmonary disease (COPD), sponsored by Neutec Group. Started Aug 2023; status: recruiting.
02
Drugs
ipratropium bromidelevalbuterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05890638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05890638.